Summary:
In Thai adults with type 2 diabetes mellitus on metformin monotherapy, Bifidobacterium animalis subsp. lactis TISTR 2591 (BA-2591) supplementation significantly improved fasting glycemia, insulin resistance, β-cell function, and select immune parameters compared to placebo over a 6-week intervention period (1 × 109 CFU/g/day), following a crossover design, though it was associated with no significant adverse effects or changes in body composition.
| PICO | Description |
|---|---|
| Population | Forty-four Thai adults (aged 35–65 years) diagnosed with type 2 diabetes mellitus, receiving metformin monotherapy. |
| Intervention | Oral administration of Bifidobacterium animalis subsp. lactis TISTR 2591 (BA-2591) at a dose of 1 × 109 CFU/g/day for 6 weeks in a randomized, double-blind, placebo-controlled, crossover trial. |
| Comparison | Placebo administration under identical study conditions; participants crossed over after a 4-week washout period. |
| Outcome | BA-2591 significantly attenuated fasting blood glucose increase (Δ = +1.143 vs. +12.570 mg/dL; p < 0.001), improved insulin resistance (HOMA-IR: Δ = +0.567 vs. +0.980; p = 0.006), and enhanced β-cell function (HOMA-β: Δ = +6.791% vs. -8.313%; p < 0.001). It also raised serum IgM and IgG levels, reduced LDL-C and cathepsin D activity, with no significant change in IL-6, adiponectin, MDA, hs-CRP, or body composition. No serious adverse effects occurred. |
Source: Khiaolaongam, Wiritphon, et al. “Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.” Read article here.
